SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences informs about cessation of director

18 Dec 2025 Evaluate
Eris Lifesciences has informed that the members of the Company had at their Fifteenth Annual General Meeting held on September 01, 2021, approved the appointment of Rajeev Dalal (DIN: 00222650) as a Non-Executive, Independent Director of the Company, to hold office for a term of five (consecutive) years commencing from December 19, 2020, to December 18, 2025. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), the term of appointment of Rajeev Dalal as a Non-Executive, Independent Director of the Company shall end on December 18, 2025. Consequently, Rajeev Dalal will cease to be a Non-Executive, Independent Director of the Company with effect from the close of business hours on December 18, 2025. Consequent upon the completion of the term of Rajeev Dalal, as a Non-Executive, Independent Director of the Company, his membership and chairmanship in various committees of the Board also cease to exist. The Board of Directors and Management of the Company extend their sincere appreciation for the valuable contributions made by Rajeev Dalal during his term. The relevant details pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, 2015, read with circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed as Annexure.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences Share Price

1322.75 7.35 (0.56%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×